Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Top Cited Papers
- 1 May 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 15 (6), 640-647
- https://doi.org/10.1016/s1470-2045(14)70080-4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Pathological Complete Response and Accelerated Drug Approval in Early Breast CancerNew England Journal of Medicine, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Trastuzumab-Related Cardiotoxicity Following Anthracycline-Based Adjuvant Chemotherapy: How Worried Should We Be?Journal of Clinical Oncology, 2010
- Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical TrialsJournal of Clinical Oncology, 2010
- A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patientsBreast Cancer Research and Treatment, 2010
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro StudyJournal of Clinical Oncology, 2010
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerNew England Journal of Medicine, 2006
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast CancerJournal of Clinical Oncology, 2005